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KEY POINTS SUMMARY 1 
 2 
• Common complications of pregnancy, such as chronic fetal hypoxia, trigger a 3 
fetal origin of cardiovascular dysfunction and programme cardiovascular disease 4 
in later life; 5 
 6 
• Sildenafil treatment protects placental perfusion and fetal growth. However, 7 
whether the effects of sildenafil transcend effects on the placenta to affect the 8 
fetus is unknown; 9 
 10 
• Using the chick embryo model, here we show that sildenafil treatment directly 11 
protects the fetal cardiovascular system in hypoxic development, and that the 12 
mechanisms of sildenafil protection includes reduced oxidative stress and 13 
increased nitric oxide bioavailability; 14 
 15 
• Sildenafil does not protect against fetal growth restriction in the chick embryo, 16 
supporting the idea that the protective effect of sildenafil on fetal growth 17 
reported in mammalian studies, including humans, is secondary to improved 18 
placental perfusion. 19 
 20 
• Therefore, sildenafil may be a good candidate for human translational 21 
antioxidant therapy to protect the chronically hypoxic fetus in adverse pregnancy.22 
3 
ABSTRACT 23 
 24 
There is a need for developing clinically translatable therapy for preventing fetal origins 25 
of cardiovascular disease in pregnancy complicated by chronic fetal hypoxia. Evidence 26 
shows that sildenafil protects placental perfusion and fetal growth. However, whether 27 
beneficial effects of sildenafil transcend onto the fetal heart and circulation in 28 
complicated development is unknown. We isolated the direct effects of sildenafil on the 29 
fetus using the chick embryo and hypothesised that sildenafil also protects fetal 30 
cardiovascular function in hypoxic development. Chick embryos (n=11 per group) were 31 
incubated in normoxia or hypoxia (14% O2) from day 1 and treated with sildenafil 32 
(4mg/kg/day) from day 13 of the 21-day incubation. Hypoxic incubation increased 33 
oxidative stress (4-hydroxynoneal, 141.1 ± 17.6% of normoxic control), reduced 34 
superoxide dismutase (60.7 ± 6.3%), increased phosphodiesterase type 5 expression 35 
(167 ± 13.7%) and decreased nitric oxide bioavailability (54.7 ± 6.1%) in the fetal heart, 36 
and promoted peripheral endothelial dysfunction (70.9 ± 5.6 AUC of normoxic control; 37 
all P < 0.05). Sildenafil treatment after onset of chronic hypoxia prevented the increase 38 
in phosphodiesterase expression (72.5 ± 22.4), protected against oxidative stress (94.7 ± 39 
6.2) and normalised nitric oxide bioavailability (115.6 ± 22.3) in the fetal heart, and 40 
restored endothelial function in the peripheral circulation (89.8 ± 2.9). Sildenafil 41 
protects the fetal heart and circulation directly in hypoxic development via mechanisms 42 
including decreased oxidative stress and enhanced nitric oxide bioavailability. Sildenafil 43 
may be a good translational candidate for human antioxidant therapy to prevent fetal 44 
origins of cardiovascular dysfunction in adverse pregnancy.  45 
 46 
Abbreviations  47 
3-NT, 3-nitrotyrosine; 4-HNE, 4-hydroxynoneal; ACh, acetylcholine; COX, 48 
cyclooxygenase; GMP, guanosine monophosphate; GPx, glutathione peroxidase; H, 49 
hypoxic; HS, hypoxic sildenafil; IUGR, intrauterine growth restriction; N, normoxic; 50 
NO, nitric oxide; NOx, nitric oxide species; NS, normoxic sildenafil; PDE5, 51 
phosphodiesterase type 5; PE, phenylephrine; SNP, sodium nitroprusside; SOD, 52 
superoxide dismutase; ROS, reactive oxygen species.  53 
4 
INTRODUCTION 54 
 55 
It is widely accepted from data derived from humans and animal models that adverse 56 
conditions during pregnancy can trigger fetal growth restriction and an early origin of 57 
cardiovascular disease (Barker et al., 1993; Gluckman et al., 2008; Giussani & Davidge, 58 
2013). Chronic fetal hypoxia is common during adverse pregnancy (Giussani, 2016) and 59 
independent studies have shown that chronic fetal hypoxia can trigger cardiovascular 60 
dysfunction in the offspring secondary to oxidative stress (Giussani et al., 2012; 61 
Patterson et al., 2012; Thompson & Al-Hasan, 2012; Giussani & Davidge, 2013). For 62 
instance, hypoxic pregnancy in rats increased levels of oxidative stress in the fetal heart 63 
and vasculature, setting cardiac sympathetic dominance and endothelial dysfunction in 64 
the adult offspring; maternal treatment with the antioxidant vitamin C was protective 65 
(Giussani et al., 2012; Kane et al., 2013). Although such studies provided proof-of-66 
principle to support the idea that maternal antioxidants protect against fetal origins of 67 
cardiovascular dysfunction in the chronically hypoxic fetus, only high doses of vitamin 68 
C incompatible with human treatment were effective. Further, in these studies maternal 69 
antioxidant therapy was administered from the onset of chronic fetal hypoxia, limiting 70 
their human translational capacity (Giussani et al., 2012; Kane et al., 2013). Clinically, 71 
diagnosis prior to treatment is necessary, therefore maternal antioxidant treatment 72 
following established chronic fetal hypoxia would provide a better translational study 73 
design.  74 
 75 
One possible alternative candidate therapy is sildenafil, the selective inhibitor of cyclic 76 
guanosine monophosphate (GMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil 77 
has direct antioxidant properties (Koupparis et al., 2005) and by preventing the 78 
hydrolysis of cyclic GMP by PDE5, it additionally increases the bioavailability of cyclic 79 
GMP, a downstream secondary messenger of the potent vasodilator nitric oxide (NO, 80 
Francis & Corbin, 2003). Sildenafil treatment in human, ovine and murine pregnancy 81 
complicated by fetal growth restriction improved placental perfusion, increasing 82 
umbilical blood flow and protecting fetal growth (Satterfield et al., 2010; von 83 
Dadelszen et al., 2011; Stanley et al., 2012; Dilworth et al., 2013). Therefore, a large 84 
5 
multicentre international scheme was recently launched to determine the efficacy of 85 
sildenafil as candidate human clinical intervention for fetal growth restriction 86 
(Ganzevoort et al., 2014). However, whether the positive effects of sildenafil transcend 87 
those on placental perfusion and fetal growth onto beneficial effects on the fetal 88 
cardiovascular system is completely unknown. Equally important, whether sildenafil 89 
has any potential adverse effects on fetal cardiovascular function in addition to effects 90 
on the maternal and/or placental physiology in healthy or complicated development is 91 
unclear.  92 
 93 
Therefore, this study isolated the effects of sildenafil on the fetal cardiovascular system 94 
using the chick embryo, the only established animal model in which the direct effects on 95 
the fetal heart and circulation of potential therapy can be investigated, independent of 96 
effects on the mother and/or the placenta. The study tested the hypothesis that sildenafil 97 
treatment has direct beneficial effects on the fetal cardiovascular system in development 98 
complicated by chronic fetal hypoxia. In addition, we proposed that mechanisms of 99 
protection include reduced oxidative stress with enhanced NO bioavailability. The 100 
hypothesis was tested by investigating the effects of normoxic or hypoxic incubation of 101 
chick embryos with or without sildenafil treatment on fetal growth, fetal peripheral 102 
vascular reactivity and on molecular indices of oxidative stress, antioxidant capacity and 103 
NO bioavailability. Treatment of chick embryos with sildenafil started at day 13 of 104 
incubation, equivalent to ca. 25 weeks of gestation in human pregnancy, a gestational 105 
age at which human fetal growth restriction can be reliably diagnosed.  106 
6 
METHODS 107 
Ethical Approval 108 
All procedures were performed under the UK Animals (Scientific Procedures) Act 1986 109 
and were approved by the Ethical Review Committee of the University of Cambridge, 110 
as described in the Editorial by Grundy (2015). 111 
 112 
Animals 113 
Fertilised Bovans Brown eggs (Medeggs, Norfolk, UK) were weighed and incubated 114 
under normoxic (21% O2) or hypoxic (14±0.5% O2) conditions (37.9°C, 45% humidity, 115 
12:12h light:dark cycle, automatic rotation every hour, Mod-75A equipped with 116 
electronic servo-controlled humidity system HS-Auto-3.5L, Marsalles, Barcelona, 117 
Spain) from day 1. The levels of oxygen, humidity and temperature inside the 118 
incubators were continuously monitored (DD103 DrDAQ Oxygen Sensor, Pico 119 
Technology, St. Neots, UK).  120 
 121 
Dose of sildenafil 122 
In clinical studies in which sildenafil has been administered to pregnant women, the 123 
dose varies between 0.86-3.43 mg/kg/d (Samangaya et al., 2009; von Dadelszen et al., 124 
2011) assuming a 60 kg body weight at pre-conception and a weight gain of 10 kg by 25 125 
weeks of gestation (Bhattacharya et al., 2007; Fraser et al., 2010). The dose of chronic 126 
sildenafil treatment used in animal studies varies between 0.5-90 mg/kg/d (Refuerzo et 127 
al., 2006; Sanchez-Aparicio et al., 2008). Notably, the metabolism of sildenafil also 128 
differs between species (Walker et al., 1999) and no pharmacokinetic study of sildenafil 129 
in the chicken has been previously reported. Collectively, from previous human and 130 
animal data available, a 4 mg/kg/d dose regimen was chosen for the present study as a 131 
dose that is human clinically as well as scientifically relevant. Therefore, chick embryos 132 
were treated with sildenafil (4mg/kg/d, Sildenafil citrate salt, Sigma-Aldrich, UK) or 133 
vehicle (100µl water) from day 13 to day 18 of incubation. Sildenafil was injected daily 134 
into the air cell onto the chorioallantoic membrane via a 1 mm hole in the eggshell of 135 
normoxic or hypoxic eggs. N = 11 eggs were used per group (normoxic control, 136 
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hypoxic control, hypoxic sildenafil, normoxic sildenafil). The hole was covered with 137 
tape at all other times. All treatment procedures were performed under sterile 138 
conditions. 139 
 140 
Haematocrit and growth analysis 141 
On day 19 of the 21 day incubation period, embryos underwent euthanasia by 142 
decapitation and immediately post mortem the weight of the embryo, yolk, extra-143 
embryonic membranes, chorioallantoic fluid and the shell was recorded and expressed 144 
as percentages of the egg weight on day 19 to determine how much resource was turned 145 
into fetal body mass within each egg. Blood was collected in micro-haematocrit tubes 146 
(Vitrex, Modulohm, Denmark) directly from the heart and the haematocrit was 147 
determined in duplicate. Body length was measured by placing the ends of a digital 148 
calliper on top of the head and the base of the tail. The heart, brain, liver, lungs and the 149 
kidneys were dissected and weighed. A section of the third order femoral artery was 150 
dissected for vascular reactivity analysis. The heart was snap frozen in liquid nitrogen 151 
and stored at -80°C until molecular analysis.  152 
 153 
Molecular studies in the chick embryo heart  154 
Alterations in the pro-oxidant indices 3-nitrotyrosine (3-NT) and 4-hydroxynoneal (4-155 
HNE), in the antioxidant enzymes superoxide dismutase (SOD), catalase and 156 
glutathione peroxidase (GPx), and in the level of NO species (NOx) were determined in 157 
the chick embryo heart at day 19 of incubation. In addition, changes in the cardiac 158 
expression of PDE5 were determined to validate the effect of sildenafil treatment.  159 
 160 
The expression of 3-NT, 4-HNE and SOD, the activity of catalase and the levels of NOx 161 
were determined by commercial assay kits according to the manufacturers’ instructions 162 
(3-NT: ab116691, Abcam, Cambridge, UK., 4-HNE: E12H0203, AMS biotechnology, 163 
Abington, UK., SOD: Sigma-Aldrich, UK., Catalase: 707002 and NOx: 78001, Cayman 164 
Chemical Company, MI, USA).  165 
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 166 
The cardiac expression of GPx and PDE5 was determined by Western Blot. Frozen 167 
chick hearts (25mg) were powdered on dry ice and homogenized in 250µl of ice-cold 168 
lysis buffer (HEPES:50mM, NaCl:150mM, Triton-X100:1%, Na3VO4:1mM, 169 
NaF:30mM, Na4P2O7:10mM, EDTA:10mM, Protease inhibitor cocktail III [Calbiochem, 170 
Nottingham, UK]) in a microtube containing 1.4 mm ceramic beads (Lysing Matrix D, 171 
MP biomedicals). The protein concentration of lysates was determined using the 172 
copper-Bicinchoninic assay (Smith et al., 1985). Protein samples were diluted with 5x 173 
Laemmli’s buffer (sodium dodecyl sulphate (SDS):2%, Tris-HCl (pH 6.8):62.5mM, 174 
glycerol:10%, dithiothreitol:100mM, bromophenol blue) then standardized to a protein 175 
concentration of 1 mg/ml by further addition of 1 x Laemmli’s buffer. Total protein (10 176 
µg) from each sample (n = 6 per treatment group) was separated on SDS-PAGE gel 177 
electrophoresis along with a pre-stained molecular weight marker (PageRuler Plus 178 
Prestained Protein Ladder 10-250kDa, Thermo Scientific, Waltham, USA), then 179 
transferred immediately to a Polyvinylidene difluoride Immobilon-P membrane (PVDF, 180 
Millipore, Billerica, MA, USA). The membrane was incubated in blocking buffer before 181 
incubation in primary antibodies (GPx, ab22604; PDE5, ab64179; Abcam) overnight at 182 
4°C. Following primary antibody incubation the membranes were incubated with the 183 
secondary antibody (Peroxidase-AffiniPure Donkey Anti-Rabbit IgG (H+L), 1:10000 in 184 
PBS with 1% marvel and 0.1% Tween 20, Jackson ImmunoResearch laboratories, PA, 185 
USA) and immunoreactivity was measured using West Pico chemiluminescent substrate 186 
(Thermo Scientific). The intensity of the bands were analysed with the AlphaEase 187 
imaging software (Alpha Innotech, San Leandro, CA, USA). Following the protein 188 
detection, the membrane was stained with 0.1% Coomassie R-250 and the intensity of 189 
the Coomassie staining for each lane was analysed (Welinder & Ekblad, 2011). The 190 
expression level of the target protein in each sample was normalised to the Coomassie 191 
staining of the same sample for a loading control. 192 
 193 
Functional peripheral vascular reactivity using in vitro wire myography  194 
Constrictor and dilator function of the peripheral resistance vasculature was assessed 195 
using a microvascular myograph (Wire Myograph System 610M; DMT, Aarhus, 196 
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Denmark) as previously described (Itani et al., 2016). Briefly, a third order femoral 197 
artery was dissected at day 19 of incubation and mounted in a chamber containing 198 
Kreb’s buffer. Vascular constrictor capacity was assessed with increasing doses of K+ 199 
solutions (16.74 – 250 mM) and of phenylephrine (PE, 10-8 – 10-4 M). The response to 200 
K+ was normalised to the diameter of the vessel (mN/mm/µm/1000). The response to 201 
phenylephrine was normalised to the constrictor response to 125mM K+ achieved by the 202 
same vessel (% K+125). Vasodilator responses to cumulative doses of sodium 203 
nitroprusside (SNP, 10-10 – 10-4 M) and of acetylcholine (ACh, 10-9 – 10-5 M) were 204 
assessed after pre-constricting the vessel with a sub-optimal dose of potassium. The 205 
partial contributions of endogenous NO-dependent and NO-independent mechanisms to 206 
the vasorelaxation were determined by repeating the ACh dose response curve after 207 
incubating the vessel with L-NAME (10-5 M, 10min) and calculating the area under the 208 
curves (Herrera et al., 2010; Itani et al., 2016). The sensitivity (pD2) to ACh was 209 
defined as –log10 (EC50). LabChart was used for data acquisition and analysis of the in 210 
vitro wire myography data (LabChart 6.0, Powerlab 8/30; AD Instruments, Chalgrove, 211 
UK).  212 
 213 
Statistical analysis 214 
All data are expressed as mean ± S.E.M. Data were checked for Gaussian distribution 215 
using the D'Agostino-Pearson normality test. Statistical comparisons were made using 216 
Two-way ANOVA, with the Bonferroni post hoc test where a significant interaction 217 
was detected. For all comparisons, statistical significance was accepted when P<0.05. 218 
(Graphpad prism version 5.00, Graphpad Software, Inc. San Diego, USA).  219 
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RESULTS 220 
Haematocrit and fetal growth 221 
Incubation under hypoxic conditions from day 1 significantly increased haematocrit in 222 
the chick embryo by day 19 (Figure 1A). Exposure to hypoxia throughout development 223 
reduced the body weight (Figure 1B) which persisted when the body weight was 224 
normalised to the egg weight at the start of incubation (N: 41.3±1.0, H: 29.0±1.3*, HS: 225 
32.0±2.2*, NS: 43.9±1.3 g/g, P < 0.05; *effect of hypoxia). Hypoxia affected the body 226 
weight more severely than the body length (N: 68.1±1.7, H: 63.2±1.0*, HS: 65.9±0.9, 227 
NS: 70.8±0.6 mm, P < 0.05; *versus N) of the embryo. Consequently, hypoxic embryos 228 
had a lower BMI (N: 5.3±0.2, H: 4.6±0.1*, HS: 4.5±0.2*, NS: 5.1±0.1 kg/m2, P < 0.05; 229 
*effect of hypoxia). The brain weight was reduced in the hypoxic embryo (N: 0.84±0.01, 230 
H: 0.73±0.02*, HS: 0.74±0.01*, NS: 0.84±0.01 g, P < 0.05; *effect of hypoxia), 231 
however this was not proportional to the reduction in their body size and thus, the 232 
relative brain weight was increased (Figure 1C). In addition, calculation of resource 233 
partitioning revealed less resource attributed to embryonic mass in hypoxic incubations 234 
(Figure 1D). Collectively, the data show that those embryos exposed to chronic hypoxia 235 
were thin for their length and had relative brain sparing. Sildenafil treatment from day 236 
13 of incubation had no effect on changes in fetal growth or brain sparing during either 237 
hypoxic or normoxic incubation (Figure 1).  238 
 239 
Exposure to chronic hypoxia from day 1 significantly reduced the weight of the heart, 240 
lungs, liver and kidneys by day 19 in the chick embryo, and this was proportional to the 241 
reduction in body size (Table 1). Sildenafil treatment in normoxic and hypoxic embryos 242 
did not affect the absolute or relative weight of the lungs, liver or kidneys. However, 243 
both absolute and relative heart weights were significantly reduced in normoxic 244 
embryos treated with sildenafil, while the relative heart weight was also reduced in 245 
hypoxic embryos treated with sildenafil (Table 1).  246 
 247 
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Molecular studies in the chick embryo heart  248 
In the heart of chick embryos exposed to chronic hypoxia, the protein expression of 249 
3-NT and 4-HNE was significantly elevated (Figure 2A and B). In addition, the 250 
expression of SOD and the activity of catalase were both decreased in the hypoxic heart 251 
(Figure 3A and B). Hypoxic incubation had no effect on the cardiac expression of GPx 252 
(Figure 3C) but the total cardiac NOx concentration was reduced (Figure 3D). Sildenafil 253 
treatment prevented the increase in 4-HNE but not 3-NT in the hypoxic embryo heart. 254 
Cardiac NOx levels were restored by sildenafil treatment in the hypoxic embryo. 255 
However the treatment significantly reduced the levels of cardiac NOx in normoxic 256 
embryos. Sildenafil treatment had no significant effect on the expression of SOD or the 257 
activity of catalase, however the protein expression of GPx in the heart of hypoxic 258 
embryos was significantly elevated (Figure 2 and 3). 259 
 260 
Compared to normoxic embryos, the protein expression of PDE5 in the heart was 261 
significantly enhanced in hypoxic embryos treated with vehicle. Sildenafil treatment of 262 
hypoxic embryos normalised the protein expression of cardiac PDE5 and sildenafil 263 
treatment of normoxic embryos showed no effect on the protein expression of cardiac 264 
PDE5 (Figure 4).  265 
 266 
Functional peripheral vascular reactivity using in vitro wire myography  267 
The femoral arterial segments displayed a dose-dependent relaxation in response to SNP 268 
and ACh (Figures 5 and 6). The femoral arterial vascular response to SNP was not 269 
significantly affected by hypoxic incubation or sildenafil treatment (Figure 6A). In 270 
contrast, incubation under hypoxic conditions shifted the ACh relaxation curve to the 271 
right, with vessels requiring higher concentrations of ACh to achieve similar relaxation 272 
(Figure 5 and 6B). Consequently, compared to normoxic embryos, the sensitivity (pD2) 273 
of the vessels to ACh was significantly reduced in hypoxic embryos. In addition the 274 
total relaxant capacity to ACh, measured as area under the curve (AUC), was 275 
significantly reduced in the hypoxic embryo (Figure 6C). The ACh relaxant curve was 276 
repeated in presence of a NO synthase blocker L-NAME to determine the partial 277 
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contributions of NO-dependent and NO–independent components of the vasodilation, 278 
which revealed that the deficit in the total femoral vascular relaxation in response to 279 
ACh in hypoxic embryos was primarily due to NO-independent mechanisms. Sildenafil 280 
treatment in hypoxic embryos rescued the vasodilation both in terms of sensitivity and 281 
total relaxation by significantly enhancing the NO-dependent component of the 282 
vasodilation (Figure 6B and C). Sildenafil treatment in normoxic embryos did not affect 283 
femoral vascular dilator function. 284 
 285 
Relative to normoxic embryos, those incubated under hypoxic conditions displayed a 286 
significantly enhanced maximal constrictor response to potassium (N: 2.4±0.2, H: 287 
4.4±0.9*, HS: 4.4±0.5*, NS: 2.5±0.3 mN/mm/µm/1000) but constrictor responses to 288 
phenylephrine were not affected (N:116 ± 4, H:118 ± 4, HS:125 ± 10, NS:124 ± 10% 289 
K+ 125 mM). Sildenafil treatment had no effect on femoral constrictor function.  290 
13 
DISCUSSION 291 
 292 
The data in this study show that hypoxic incubation of the chick embryo led to an 293 
increase in fetal haematocrit and promoted asymmetric fetal growth restriction by the 294 
end of the incubation period. Hypoxic incubation increased levels of oxidative stress in 295 
the fetal heart, reduced cardiac antioxidant defences, increased cardiac PDE5 expression, 296 
decreased cardiac NO bioavailability and promoted endothelial dysfunction in 297 
peripheral resistance vessels. Treatment of the chronically hypoxic chick embryo with 298 
sildenafil long after the onset of chronic hypoxia prevented the increase in cardiac 299 
PDE5 expression, protected against cardiac oxidative stress, normalised cardiac NO 300 
bioavailability and restored peripheral endothelial function. Therefore, the data support 301 
the hypothesis tested that sildenafil has direct beneficial effects on the fetal 302 
cardiovascular system in development complicated by chronic fetal hypoxia.  303 
 304 
In addition to its obvious advantages of higher throughput and lower cost over other 305 
animal models, the chick embryo is the only established animal model that permits 306 
isolation of the direct effects on the fetus of developmental hypoxia, oxidative stress 307 
and/or treatment independent of additional effects of the experimental design on 308 
maternal nutrition or changes in the placental and/or maternal physiology. The ontogeny 309 
of cardiac development in the chicken is much more comparable to the human than the 310 
rat or the mouse (Marcela et al., 2012). Further, mechanisms underlying the control of 311 
cardiovascular function in the chick embryo and the human fetus show many 312 
similarities (Crossley & Altimiras, 2000; Mulder et al., 2000; Ruijtenbeek et al., 2002; 313 
Giussani, 2016). Consequently, the chick embryo model has been used by independent 314 
groups to isolate the effects on fetal growth and on fetal cardiovascular function of 315 
development complicated by chronic fetal hypoxia (Ruijtenbeek et al., 2000; 316 
Dzialowski et al., 2002; Rouwet et al., 2002; Sharma et al., 2006; Salinas et al., 2010; 317 
Giussani, 2016; Itani et al., 2016). 318 
 319 
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Accumulating evidence shows that PDE5 is involved in many cardiac disease states 320 
where perturbations in NO signalling is implicated (Kass et al., 2007). The expression 321 
of PDE5 is up-regulated in the left ventricle in patients with end-stage ischemic or 322 
dilated cardiomyopathy (Pokreisz et al., 2009) and in hypertrophied hearts (Nagendran 323 
et al., 2007). Importantly, the increase in myocardial PDE5 in the failing heart is 324 
associated with increased levels of cardiac 3-NT and 4-HNE (Lu et al., 2010). Chronic 325 
hypoxia also stimulates a number of pro-oxidant pathways such as xanthine-oxidase 326 
(Kane et al., 2014), as well as consuming a number of antioxidant defences (Maiti et al., 327 
2006; Giussani & Davidge, 2013). In the present study, treatment with sildenafil 328 
prevented the chronic hypoxia-induced increase in PDE5 and in 4-HNE, it increased 329 
glutathione and restored NO bioavailability in the chick embryo heart. 4-HNE is a 330 
major product of lipid peroxidation and it is formed via several ROS-dependent 331 
pathways (Spickett, 2013). GPx is an established antioxidant enzyme (Masella et al., 332 
2005). Therefore, the restored levels of NOx and 4-HNE coupled with the enhanced 333 
levels of GPx in the heart of sildenafil-treated hypoxic chick embryos support direct 334 
antioxidant mechanisms of sildenafil on the fetal cardiovascular system.  335 
 336 
Additional data presented in this study show that exposure to chronic hypoxia during 337 
development leads to impaired dilation in the peripheral vasculature, predominantly 338 
through NO-independent mechanisms. The binding of ACh to its trans-membrane 339 
receptors on the endothelial cell increases the level of intracellular calcium (Ca2+), 340 
releasing arachidonic acid within the cell that is, in turn, converted into prostaglandins 341 
by cyclooxygenases COX1 and COX2 (Bachschmid et al., 2005). During chronic 342 
hypoxia, arachidonic acid is preferentially converted into constrictor prostaglandins, 343 
such as TXA2 and PGF2α via enhanced COX2 activity (Fike et al., 2005; Wong et al., 344 
2009). It is well known that hypoxia at the tissue level leads to an increased generation 345 
of ROS, particularly the superoxide anion (•O2-) at the mitochondria (Chandel et al., 346 
1998; Becker et al., 1999). •O2- readily combines with NO to limit its bioavailability 347 
(Kissner et al., 1997; Thakor et al., 2010b). Therefore, chronic hypoxia shifts the 348 
cardiovascular phenotype into one of oxidative stress as well as switching the 349 
metabolism of arachidonic acid towards constrictor pathways (Fike et al., 2005; 350 
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Delannoy et al., 2010; Giussani, 2016). In the present study, treatment with sildenafil of 351 
hypoxic chick embryos restored the endothelium-dependent relaxation of the femoral 352 
artery by enhancing NO-dependent mechanisms. This agrees with the principal dilator 353 
mechanism of action of sildenafil, enhancing downstream signalling of NO. The ratio of 354 
•O2-:NO yields a vascular oxidant tone and we have shown that this is functional in fetal 355 
life and that it can be manipulated in favour of dilation (Thakor et al., 2010a; Thakor et 356 
al., 2010b; Giussani et al., 2012; Kane et al., 2014). Mechanisms in addition to 357 
antioxidant properties underlying the beneficial effects of sildenafil in the chronically 358 
hypoxic fetus therefore include inhibition of the degradation of cyclic GMP by PDE5, 359 
enhancing the action of NO, thereby normalising the vascular oxidant tone and 360 
endothelial function.  361 
 362 
Other data in the present study show that the femoral maximal contractile response to 363 
potassium was significantly enhanced in the chick embryo exposed to chronic hypoxia. 364 
The hypoxia-induced increase in the femoral contractile capacity in the chronically 365 
hypoxic chick embryo may be a direct effect of hypoxia and/or secondary to the known 366 
effects of chronic hypoxia in promoting sympathetic hyperinnervation (Ruijtenbeek et 367 
al., 2000). The latter has also been associated with proliferation and differentiation of 368 
vascular smooth muscle cells (le Noble et al., 2000; Rouwet et al., 2002). In the present 369 
study, sildenafil treatment did not diminish the magnitude of the femoral constrictor 370 
responses to either phenylephrine or to potassium, further supporting that the 371 
mechanism of action mediating the improved peripheral vasodilation is via enhancing 372 
NO-dependent actions rather than by depressing constrictor mechanisms.  373 
 374 
In the present study, treatment with sildenafil of hypoxic chick embryos did not 375 
improve the fetal growth restriction but brain sparing in growth-restricted fetuses was 376 
preserved. Alterations in the ratio of •O2-:NO promoting a vascular oxidant tone may 377 
have a significant effect on circulations which are particularly sensitive to NO, such as 378 
the placental and umbilical vascular bed (Derks et al., 2010; Thakor et al., 2010a). In 379 
support, a number of studies in humans and mammalian animal models have reported 380 
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possible protection by sildenafil against fetal growth restriction secondary to improved 381 
placental perfusion in complicated pregnancy (Refuerzo et al., 2006; Sanchez-Aparicio 382 
et al., 2008; Satterfield et al., 2010; von Dadelszen et al., 2011; Herraiz et al., 2012; 383 
Stanley et al., 2012; Dilworth et al., 2013). In the present study, sildenafil did not 384 
prevent growth restriction in the chronically hypoxic chick embryo, supporting a 385 
protective effect of sildenafil on fetal growth in mammalian species by improving 386 
placental perfusion. Alternatively, it could be argued that sildenafil treatment in this 387 
model of hypoxic development started too late following the onset of chronic fetal 388 
hypoxia to prevent fetal growth restriction.  389 
 390 
In conclusion, we have intertwined the use of the chick embryo with hypoxic incubation 391 
to provide the first evidence that sildenafil has direct protective effects on the fetal heart 392 
and vasculature, independent of the presence of a placenta. The mechanisms underlying 393 
the protection conveyed by sildenafil on the fetal cardiovascular system include 394 
inhibition of PDE5, increased antioxidant defences, diminished oxidative stress, 395 
increased NO bioavailability and diminished NO-dependent endothelial dysfunction. 396 
The protective effects of sildenafil on the cardiovascular system of the chronically 397 
hypoxic fetus were evident even when sildenafil therapy was started long after the onset 398 
of chronic hypoxia. The lack of a protective effect of sildenafil treatment on fetal 399 
growth in the chick embryo during hypoxic development supports beneficial effects of 400 
sildenafil on growth in IUGR fetuses of mammalian species, including humans, to be at 401 
the level of the placenta. Future research will therefore need to consider direct and 402 
indirect effects of sildenafil at the maternal, placental and fetal levels. However, 403 
sildenafil offers to be a plausible candidate for human clinical translational therapy to 404 
rescue adverse effects of pregnancy complicated by developmental hypoxia.  405 
  406 
17 
REFERENCES 407 
Bachschmid M, Schildknecht S & Ullrich V. (2005). Redox regulation of vascular prostanoid 408 
synthesis by the nitric oxide-superoxide system. Biochem Biophys Res Commun 338, 409 
536-542. 410 
 411 
Barker DJ, Osmond C, Simmonds SJ & Wield GA. (1993). The relation of small head 412 
circumference and thinness at birth to death from cardiovascular disease in adult life. 413 
BMJ 306, 422-426. 414 
 415 
Becker LB, vanden Hoek TL, Shao ZH, Li CQ & Schumacker PT. (1999). Generation of superoxide 416 
in cardiomyocytes during ischemia before reperfusion. Am J Physiol 277, H2240-2246. 417 
 418 
Bhattacharya S, Campbell DM, Liston WA & Bhattacharya S. (2007). Effect of Body Mass Index 419 
on pregnancy outcomes in nulliparous women delivering singleton babies. BMC Public 420 
Health 7, 168. 421 
 422 
Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC & Schumacker PT. (1998). 423 
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl 424 
Acad Sci U S A 95, 11715-11720. 425 
 426 
Crossley D & Altimiras J. (2000). Ontogeny of cholinergic and adrenergic cardiovascular 427 
regulation in the domestic chicken (Gallus gallus). Am J Physiol Regul Integr Comp 428 
Physiol 279, R1091-1098. 429 
 430 
Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R & Muller B. (2010). Hypoxia-431 
induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, 432 
and thromboxane receptors. Cardiovasc Res 85, 582-592. 433 
 434 
Derks JB, Oudijk MA, Torrance HL, Rademaker CM, Benders MJ, Rosen KG, Cindrova-Davies T, 435 
Thakor AS, Visser GH, Burton GJ, van Bel F & Giussani DA. (2010). Allopurinol reduces 436 
oxidative stress in the ovine fetal cardiovascular system after repeated episodes of 437 
ischemia-reperfusion. Pediatr Res 68, 374-380. 438 
 439 
Dilworth MR, Andersson I, Renshall LJ, Cowley E, Baker P, Greenwood S, Sibley CP & Wareing 440 
M. (2013). Sildenafil citrate increases fetal weight in a mouse model of fetal growth 441 
restriction with a normal vascular phenotype. PLoS One 8, e77748. 442 
 443 
Dzialowski EM, von Plettenberg D, Elmonoufy NA & Burggren WW. (2002). Chronic hypoxia 444 
alters the physiological and morphological trajectories of developing chicken embryos. 445 
Comp Biochem Physiol A Mol Integr Physiol 131, 713-724. 446 
 447 
18 
Fike CD, Kaplowitz MR, Zhang Y & Pfister SL. (2005). Cyclooxygenase-2 and an early stage of 448 
chronic hypoxia-induced pulmonary hypertension in newborn pigs. J Appl Physiol 449 
(1985) 98, 1111-1118; discussion 1091. 450 
 451 
Francis SH & Corbin JD. (2003). Molecular mechanisms and pharmacokinetics of 452 
phosphodiesterase-5 antagonists. Curr Urol Rep 4, 457-465. 453 
 454 
Fraser A, Tilling K, Macdonald-Wallis C, Sattar N, Brion MJ, Benfield L, Ness A, Deanfield J, 455 
Hingorani A, Nelson SM, Smith GD & Lawlor DA. (2010). Association of maternal weight 456 
gain in pregnancy with offspring obesity and metabolic and vascular traits in 457 
childhood. Circulation 121, 2557-2564. 458 
 459 
Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-460 
Leemhuis A, Gluud C, Mol BW & Baker PN. (2014). STRIDER: Sildenafil Therapy In 461 
Dismal prognosis Early-onset intrauterine growth Restriction--a protocol for a 462 
systematic review with individual participant data and aggregate data meta-analysis 463 
and trial sequential analysis. Systematic reviews 3, 23. 464 
 465 
Giussani DA. (2016). The fetal brain sparing response to hypoxia: physiological mechanisms. J 466 
Physiol 594, 1215-1230. 467 
 468 
Giussani DA, Camm EJ, Niu Y, Richter HG, Blanco CE, Gottschalk R, Blake EZ, Horder KA, Thakor 469 
AS, Hansell JA, Kane AD, Wooding FB, Cross CM & Herrera EA. (2012). Developmental 470 
programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. 471 
PLoS One 7, e31017. 472 
 473 
Giussani DA & Davidge ST. (2013). Developmental programming of cardiovascular disease by 474 
prenatal hypoxia. J Dev Orig Health Dis 4, 328-337. 475 
 476 
Gluckman PD, Hanson MA, Cooper C & Thornburg KL. (2008). Effect of in utero and early-life 477 
conditions on adult health and disease. N Engl J Med 359, 61-73. 478 
 479 
Grundy D. (2015). Principles and standards for reporting animal experiments in The Journal of 480 
Physiology and Experimental Physiology. J Physiol 593, 2547-2549. 481 
 482 
Herraiz S, Pellicer B, Serra V, Cauli O, Cortijo J, Felipo V & Pellicer A. (2012). Sildenafil citrate 483 
improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG 119, 1394-1402. 484 
 485 
Herrera EA, Verkerk MM, Derks JB & Giussani DA. (2010). Antioxidant treatment alters 486 
peripheral vascular dysfunction induced by postnatal glucocorticoid therapy in rats. 487 
PLoS One 5, e9250. 488 
19 
 489 
Itani N, Skeffington KL, Beck C, Niu Y & Giussani DA. (2016). Melatonin rescues cardiovascular 490 
dysfunction during hypoxic development in the chick embryo. J Pineal Res 60, 16-26. 491 
 492 
Kane AD, Hansell JA, Herrera EA, Allison BJ, Niu Y, Brain KL, Kaandorp JJ, Derks JB & Giussani 493 
DA. (2014). Xanthine oxidase and the fetal cardiovascular defence to hypoxia in late 494 
gestation ovine pregnancy. J Physiol 592, 475-489. 495 
 496 
Kane AD, Herrera EA, Camm EJ & Giussani DA. (2013). Vitamin C prevents intrauterine 497 
programming of in vivo cardiovascular dysfunction in the rat. Circ J 77, 2604-2611. 498 
 499 
Kass DA, Takimoto E, Nagayama T & Champion HC. (2007). Phosphodiesterase regulation of 500 
nitric oxide signaling. Cardiovasc Res 75, 303-314. 501 
 502 
Kissner R, Nauser T, Bugnon P, Lye PG & Koppenol WH. (1997). Formation and properties of 503 
peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow 504 
technique, and pulse radiolysis. Chem Res Toxicol 10, 1285-1292. 505 
 506 
Koupparis AJ, Jeremy JY, Muzaffar S, Persad R & Shukla N. (2005). Sildenafil inhibits the 507 
formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the 508 
thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 509 
96, 423-427. 510 
 511 
le Noble FA, Ruijtenbeek K, Gommers S, de Mey JG & Blanco CE. (2000). Contractile and 512 
relaxing reactivity in carotid and femoral arteries of chicken embryos. Am J Physiol 513 
Heart Circ Physiol 278, H1261-1268. 514 
 515 
Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker 516 
M, Hall JL, Garry DJ & Chen Y. (2010). Oxidative stress regulates left ventricular PDE5 517 
expression in the failing heart. Circulation 121, 1474-1483. 518 
 519 
Maiti P, Singh SB, Sharma AK, Muthuraju S, Banerjee PK & Ilavazhagan G. (2006). Hypobaric 520 
hypoxia induces oxidative stress in rat brain. Neurochem Int 49, 709-716. 521 
 522 
Marcela SG, Cristina RM, Angel PG, Manuel AM, Sofia DC, Patricia de LR, Bladimir RR & 523 
Concepcion SG. (2012). Chronological and morphological study of heart development 524 
in the rat. Anat Rec (Hoboken) 295, 1267-1290. 525 
 526 
Masella R, Di Benedetto R, Vari R, Filesi C & Giovannini C. (2005). Novel mechanisms of natural 527 
antioxidant compounds in biological systems: involvement of glutathione and 528 
glutathione-related enzymes. J Nutr Biochem 16, 577-586. 529 
20 
 530 
Mulder AL, Golde JM, Goor AA, Giussani DA & Blanco CE. (2000). Developmental changes in 531 
plasma catecholamine concentrations during normoxia and acute hypoxia in the chick 532 
embryo. J Physiol 527 Pt 3, 593-599. 533 
 534 
Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, 535 
Rebeyka IM, Ross DB, Light PE, Dyck JR & Michelakis ED. (2007). Phosphodiesterase 536 
type 5 is highly expressed in the hypertrophied human right ventricle, and acute 537 
inhibition of phosphodiesterase type 5 improves contractility. Circulation 116, 238-538 
248. 539 
 540 
Patterson AJ, Xiao D, Xiong F, Dixon B & Zhang L. (2012). Hypoxia-derived oxidative stress 541 
mediates epigenetic repression of PKCepsilon gene in foetal rat hearts. Cardiovasc Res 542 
93, 302-310. 543 
 544 
Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, 545 
Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, 546 
Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD & 547 
Janssens SP. (2009). Ventricular phosphodiesterase-5 expression is increased in 548 
patients with advanced heart failure and contributes to adverse ventricular remodeling 549 
after myocardial infarction in mice. Circulation 119, 408-416. 550 
 551 
Refuerzo JS, Sokol RJ, Aranda JV, Hallak M, Hotra JW, Kruger M & Sorokin Y. (2006). Sildenafil 552 
citrate and fetal outcome in pregnant rats. Fetal Diagn Ther 21, 259-263. 553 
 554 
Rouwet EV, Tintu AN, Schellings MW, van Bilsen M, Lutgens E, Hofstra L, Slaaf DW, Ramsay G & 555 
Le Noble FA. (2002). Hypoxia induces aortic hypertrophic growth, left ventricular 556 
dysfunction, and sympathetic hyperinnervation of peripheral arteries in the chick 557 
embryo. Circulation 105, 2791-2796. 558 
 559 
Ruijtenbeek K, De Mey JG & Blanco CE. (2002). The chicken embryo in developmental 560 
physiology of the cardiovascular system: a traditional model with new possibilities. Am 561 
J Physiol Regul Integr Comp Physiol 283, R549-550; author reply R550-541. 562 
 563 
Ruijtenbeek K, le Noble FA, Janssen GM, Kessels CG, Fazzi GE, Blanco CE & De Mey JG. (2000). 564 
Chronic hypoxia stimulates periarterial sympathetic nerve development in chicken 565 
embryo. Circulation 102, 2892-2897. 566 
 567 
Salinas CE, Blanco CE, Villena M, Camm EJ, Tuckett JD, Weerakkody RA, Kane AD, Shelley AM, 568 
Wooding FB, Quy M & Giussani DA. (2010). Cardiac and vascular disease prior to 569 
hatching in chick embryos incubated at high altitude. J Dev Orig Health Dis 1, 60-66. 570 
 571 
21 
Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A & Baker PN. (2009). A 572 
randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 573 
5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 28, 369-574 
382. 575 
 576 
Sanchez-Aparicio P, Mota-Rojas D, Nava-Ocampo AA, Trujillo-Ortega ME, Alfaro-Rodriguez A, 577 
Arch E & Alonso-Spilsbury M. (2008). Effects of sildenafil on the fetal growth of guinea 578 
pigs and their ability to survive induced intrapartum asphyxia. Am J Obstet Gynecol 579 
198, 127 e121-126. 580 
 581 
Satterfield MC, Bazer FW, Spencer TE & Wu G. (2010). Sildenafil citrate treatment enhances 582 
amino acid availability in the conceptus and fetal growth in an ovine model of 583 
intrauterine growth restriction. J Nutr 140, 251-258. 584 
 585 
Sharma SK, Lucitti JL, Nordman C, Tinney JP, Tobita K & Keller BB. (2006). Impact of hypoxia on 586 
early chick embryo growth and cardiovascular function. Pediatr Res 59, 116-120. 587 
 588 
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, 589 
Goeke NM, Olson BJ & Klenk DC. (1985). Measurement of protein using bicinchoninic 590 
acid. Anal Biochem 150, 76-85. 591 
 592 
Spickett CM. (2013). The lipid peroxidation product 4-hydroxy-2-nonenal: Advances in 593 
chemistry and analysis. Redox Biol 1, 145-152. 594 
 595 
Stanley JL, Andersson IJ, Poudel R, Rueda-Clausen CF, Sibley CP, Davidge ST & Baker PN. (2012). 596 
Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout 597 
mouse model. Hypertension 59, 1021-1028. 598 
 599 
Thakor AS, Herrera EA, Seron-Ferre M & Giussani DA. (2010a). Melatonin and vitamin C 600 
increase umbilical blood flow via nitric oxide-dependent mechanisms. J Pineal Res 49, 601 
399-406. 602 
 603 
Thakor AS, Richter HG, Kane AD, Dunster C, Kelly FJ, Poston L & Giussani DA. (2010b). Redox 604 
modulation of the fetal cardiovascular defence to hypoxaemia. J Physiol 588, 4235-605 
4247. 606 
 607 
Thompson LP & Al-Hasan Y. (2012). Impact of oxidative stress in fetal programming. J 608 
Pregnancy 2012, 582748. 609 
 610 
von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller 611 
SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, Research into Advanced 612 
22 
Fetal D & Therapy G. (2011). Sildenafil citrate therapy for severe early-onset 613 
intrauterine growth restriction. BJOG 118, 624-628. 614 
 615 
Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P & Wright PA. (1999). 616 
Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. 617 
Xenobiotica 29, 297-310. 618 
 619 
Welinder C & Ekblad L. (2011). Coomasie Staining as Lading Control in Western Blot Analysis. J 620 
Proteome Res 10, 1416-1419. 621 
 622 
Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, Chen ZY, Vanhoutte PM, Gollasch M & 623 
Huang Y. (2009). Cyclooxygenase-2-derived prostaglandin F2alpha mediates 624 
endothelium-dependent contractions in the aortae of hamsters with increased impact 625 
during aging. Circ Res 104, 228-235. 626 
 627 
 
ADDITIONAL INFORMATION 628 
None 629 
COMPETING INTERESTS 630 
None 631 
AUTHOR CONTRIBUTIONS 632 
All experiments were performed at The University of Cambridge. Conception and 633 
design of experiments and analysis of data: NI, KLS, CB and DAG. Editing of the 634 
article: NI, DAG. All authors approve the final version of the manuscript and agree to 635 
be accountable for all aspects of the work in ensuring that questions related to the 636 
accuracy or integrity of any part of the work are appropriately investigated and resolved. 637 
All persons designated as authors qualify for authorship, and all those who qualify for 638 
authorship are listed.  639 
 640 
FUNDING 641 
Supported by the British Heart Foundation. Dino Giussani is the Professor of 642 
Cardiovascular Developmental Physiology & Medicine at the Department of 643 
Physiology Development & Neuroscience at the University of Cambridge, Professorial 644 
23 
Fellow and Director of Studies in Medicine at Gonville & Caius College, a Lister 645 
Institute Fellow and a Royal Society Wolfson Research Merit Award Holder. 646 
 647 
AUTHORS TRANSLATIONAL PERSPECTIVE 648 
Accumulating data derived from humans and animal models of complicated pregnancy 649 
support potential beneficial effects of sildenafil in improving placental perfusion and 650 
protecting fetal growth. These findings have served as the basis for launching the 651 
STRIDER clinical trials, a large multi-centre international scheme to determine the 652 
efficacy of sildenafil as candidate clinical interventional therapy to improve fetal growth 653 
restriction. However, whether the positive effects of sildenafil transcend those on 654 
placental perfusion and fetal growth onto beneficial effects on the fetal cardiovascular 655 
system was unknown. Equally important, whether sildenafil has any potential adverse 656 
effects on fetal cardiovascular function in healthy or complicated development was 657 
unclear. Here, we show that sildenafil has direct protective effects on the developing 658 
cardiovascular system of the chronically hypoxic fetus. Further, these protective effects 659 
are evident when sildenafil therapy is started long after the onset of chronic fetal 660 
hypoxia. This is useful from a human clinical perspective, as therapy can only be 661 
administered once fetal growth restriction as a result of chronic fetal hypoxia is 662 
diagnosed around 25 weeks of gestation. Therefore, sildenafil may be a good candidate 663 
for human translational antioxidant therapy to protect the chronically hypoxic fetus in 664 
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TABLE 667 
  
N 
  
H 
  
HS 
  
NS 
  
Overall effect of  
Mean SEM Mean SEM Mean SEM Mean SEM Hypoxia Sildenafil
Heart 0.2 0.01   0.14 0.01 * 0.13 0.01 * 0.17 0  † P<0.0001 
Lung 0.24 0.01 0.14 0.02 * 0.16 0.01 * 0.23 0.01 P<0.0001 
Liver 0.57 0.02 0.39 0.02 * 0.42 0.01 * 0.53 0.02 P<0.0001 
Kidney 0.23 0.01 0.16 0.02 * 0.18 0.01 * 0.23 0.01 P<0.0001 
24 
Heart/BW 0.77 0.02 0.8 0.04 0.66 0.03 † 0.67 0.02 † P<0.0001
Lung/BW 0.92 0.03 0.84 0.11 0.85 0.06 0.91 0.03
Liver/BW 2.16 0.08 2.15 0.1 2.21 0.08 2.07 0.04
Kidney/BW 0.88 0.03 0.89 0.07 0.91 0.05 0.89 0.03
 668 
Table 1. Organ weight of chick embryos at day 19 of incubation. Values are mean 669 
and S.E.M at day 19 of absolute (in grams) and relative organ weights (to body weight, 670 
BW, in grams/grams) of chick embryos incubated in either N (n=11), H (n=10), HS 671 
(n=10) or NS (n=11). Significant (P<0.05) differences are: * effect of hypoxia (N vs. H 672 
and NS vs. HS): † effect of sildenafil (N vs. NS and H vs. HS). Two-way ANOVA. 673 
There was no interaction found between the effect of hypoxia and of sildenafil treatment.  674 
FIGURES 675 
 676 
Figure 1. Haematocrit and fetal biometry. Values are mean ± S.E.M at day 19 of 677 
haematocrit (A), embryo weight (B), brain weight relative to body weight (C) and 678 
resource partitioning (D) of chick embryos incubated in either normoxia (N, n=11), 679 
hypoxia (H, n=10), hypoxia with sildenafil (HS, n=10) or normoxia with sildenafil (NS, 680 
n=11). Significant (P<0.05) differences are: * effect of hypoxia (N vs. H and NS vs. 681 
HS). Two-way ANOVA. There was no interaction found between the effect of hypoxia 682 
and of sildenafil treatment.  683 
Figure 2. Pro-oxidant mechanisms. Values are mean ± S.E.M. at day 19 of the 684 
expression of 3-NT (A) and 4-HNE (B) in the heart of chick embryos incubated in 685 
either N, H, HS or NS. n = 8, 8, 9, 9, respectively. Significant (P<0.05) differences are: 686 
* effect of hypoxia (N vs. H and NS vs. HS): † effect of sildenafil (N vs. NS and H vs. 687 
HS). Two-way ANOVA with no interaction (A) or with interaction and Bonferroni post 688 
hoc test (B).  689 
Figure 3. Anti-oxidant mechanisms and NO bioavailability. Values are mean ± 690 
S.E.M. at day 19 of the expression of SOD (A), the activity of catalase (B), the 691 
expression of GPx (C), and the concentration of NOx (D) in the heart of chick embryos 692 
25 
incubated in either N, H, HS or NS. n = 9, 9, 8, 8 for A and B. n = 6 for all groups for C. 693 
n = 8, 8, 9, 9, respectively, for D. Significant (P<0.05) differences are: * effect of 694 
hypoxia (N vs. H and NS vs. HS): † effect of sildenafil (N vs. NS and H vs. HS). Two-695 
way ANOVA with no interaction (A, B and C) or with interaction and Bonferroni post 696 
hoc test (D).  697 
Figure 4. Cardiac PDE5 expression. Values are mean ± S.E.M. at day 19 for the 698 
expression of PDE5 protein in the heart of chick embryos incubated in either N, H, HS 699 
or NS. n = 6 for all groups. Significant (P<0.05) differences are: * effect of hypoxia (N 700 
vs. H): † effect of sildenafil (H vs. HS). Two-way ANOVA with interaction and 701 
Bonferroni post hoc test.  702 
 703 
Figure 5. Representative recording of the acetylcholine dose-response curves. Example 704 
recordings of a femoral arterial segment of 2mm that was exposed to cumulative doses 705 
of acetylcholine (ACh) isolated from chick embryos incubated in either N, H, HS or NS. 706 
The traces are shown as time (minutes, horizontal axis) vs. vascular wall tension 707 
(mN/mm, vertical axis). The ACh doses were given at two minute intervals. 708 
Concentration of ACh are shown as –log10 M.  709 
 710 
 Figure 6. Peripheral vasodilator function. Values are mean ± S.E.M. for relaxant 711 
responses to SNP (A) and to ACh (B) and vasodilatation to ACh expressed as area 712 
under the curve before and after L-NAME treatment (AUC, C) for femoral arterial 713 
segments isolated from chick embryos incubated in either N, H, HS and NS. n = 10 for 714 
all groups. In (C) the AUC represents ACh-induced relaxation (complete bar with 715 
positive S.E.M.), for ACh-induced relaxation following treatment with L-NAME (NO-716 
independent component, grey bar with negative S.E.M.), and for the remaining AUC 717 
after ACh with L-NAME (NO-dependent component, black bar with negative white 718 
S.E.M). Significant (P<0.05) differences are: * effect of hypoxia (N vs. H): † effect of 719 
sildenafil (H vs. HS) for pD2 (B) and AUC (C) . Two-way ANOVA with interaction 720 
and Bonferroni post hoc test.  721 






